Health Condition 1: F200- Paranoid schizophrenia
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Control Intervention1: Not applicable: Not applicable
Sponsors
Government Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with primary diagnosis of schizophrenia as per ICD- 11 2. Patients on follow up for at least 6 months 3. Patients/ Nominated representative willing to give written informed consent 4. Patients accompanied by a reliable informant 5. Patients between 18-65 years of age 6. Any gender
Exclusion criteria
Exclusion criteria: 1. Patients already diagnosed with co-morbid psychiatric disorder such as anxiety disorders, depressive disorders, obsessive compulsive disorders, mood disorders and organic disorders. 2. Uncooperative, violent and actively suicidal patients. 3. Persons with co-morbid substance dependence except nicotine and caffeine. 4. Patients with co-morbid Intellectual disability, Alzheimer’s disease, dementia and other neurodegenerative disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence, socio-demographic and clinical correlates of polypharmacy in schizophreniaTimepoint: Baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of polypharmacy on psychopathology, quality of life, global functioning, cognitive functions assessed by PANSS, YMRS, CDSS, CGI- S, WHO QOL BREF, GAF, MOCA & the side effects associated with polypharmacy in schizophrenia patientsTimepoint: Baseline | — |
Countries
India
Contacts
Public ContactDr Ajeet Sidana
Government Medical College and Hospital
Outcome results
None listed